Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Q1 2023 Earnings Presentation
58 slides from Sanofi Sa's earnings presentation, Apr 27, 2023
Slide 1: Strong start into 2023
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices
Slide 2: Q1 2023 Results: Play to Win
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Q1 2023 Results Play to Win April 27, 2023
Slide 3: Forward-looking statements
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that
Slide 4: Agenda
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Agenda 01 Strong start into 2023 Paul Hudson 02 R&D update Dietmar Berger 03 Business update Bill Sibold, Thomas Triomphe, Olivier Charmeil & Julie Van Ongevalle 04 Financial performance and outlook 2023
Slide 5: Strong start into 2023
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Strong start into 2023
Slide 6: Q1 2023: Strong growth driven by Specialty Care, Vaccines & CHC
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Q1 2023: Strong growth driven by Specialty Care, Vaccines & CHC Specialty Care Vaccines GenMed Total sales up 5.5% €4.3bn €1.2bn €3.3bn +18.3% +15.2% -11.4% 3 GBUs with double-digit growth GenMed with sol
Slide 7: Advancing the pipeline: Steppingstones for future growth
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Advancing the pipeline: Steppingstones for future growth Key events in Q1 2023 ALTUVIIIO™ Dupixent® launch COPD readout Fitusiran Tzield® data publication acquisition 1 1. Subject to customary closing con
Slide 8: Play to Win: Leverage innovation to drive next growth chapter
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Play to Win: Leverage innovation to drive next growth chapter Toda y 2020-2022 2023-2025 2026-2030 Refocus with Transformative Industry leader in immunology decisive actions launches with >€22bn sales by
Slide 9: Upcoming investor events
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Upcoming investor events ATS Investor call Vaccines event R&D Day May 22, Washington DC June 29, London H2 2023 9 Investor Relations
Slide 10: R&D update
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D update
Slide 11: Immunology franchise: Lead Expand Disrupt
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Immunology franchise Core TAs Science driven Lead Expand Disrupt Key Type 2 Breakthrough Transformative inflammatory medicines beyond technologies diseases Type 2 11 Investor Relations
Slide 12: Dupixent positive results in uncontrolled COPD from BOREAS trial
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Dupixent (dupilumab) – positive results in uncontrolled ® COPD patients from BOREAS trial Phase 3 BOREAS trial design: Key findings Assess safety and efficacy in 939 patients, Significant, clinically mean
Slide 13: Potential to lead in COPD with two biologics
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Potential to lead in COPD with two biologics to address uncontrolled COPD in patients who failed standard of care Patient population Dupixent® and itepekimab - two distinct mechanisms of action G71 – 2035
Slide 14: Business update
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices
Slide 15: Strong immunology pipeline with 12 novel molecules
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Strong immunology pipeline with 12 novel molecules to build and expand in leading franchise Orals Injectables rilzabrutinib (BTKi) Dupixent® AD IRAK4 degrader amlitelimab (anti-OX40L) Dermatology CSU rilz
Slide 16: Neurology: A strong pipeline in multiple sclerosis
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Neurology: A strong pipeline in multiple sclerosis Multiple sclerosis is a serious, life-long neuro- degenerative disease affecting more than 2.3m tolebrutinib First pivotal readout people worldwide (BTK
Slide 17: Oncology: Scientific presence at AACR 2023
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Oncology: Scientific presence at AACR 2023 Anti-CEACAM5/Topo1K Additional abstracts Planning to move to Phase 1 in CRC later this year presented at Overall Response Rate Selective inhibition, Well tolerat
Slide 18: Business update Q1 2023
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Business update Q1 2023
Slide 19: Specialty Care performance
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Specialty Care performance €4.3bn sales +18.3% Q1 2023 Dupixent® Dupixent® Strong demand in Q1 across geographies, demographics and new indications conti
Slide 20: Dupixent off to a strong start towards €10bn in 2023
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Dupixent - off to a strong start towards €10bn in 2023 ® Global Dupixent® sales (€m) Q1 performance 2,316 Worldwide growth of Ex-U.S. contributing Ex-U.S
Slide 21: Defining a new standard for Hemophilia A
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Defining a new standard for Hemophilia A Strong launch indicators, including direct contracts with customers who account for >90% of total Hem A purchase
Slide 22: Vaccines performance
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Vaccines performance €1.2bn sales +15.2% Q1 2023 Growth driven by delivery of Influenza Polio COVID-19 contracts and recovery €63m Pertussis / Hib of Tra
Slide 23: Sanofi Vaccines leading with innovation
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Sanofi Vaccines leading with innovation Beyfortus® Consistent and high efficacy of c.80% against RSV LRTI Ability to protect all infants against all clin
Slide 24: GenMed performance
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare GenMed performance €3.3bn sales -11.4% Q1 2023 Core assets on track Core assets Non-core assets Robust growth of Praluent® and Rezurock® €1,617m €1,520m
Slide 25: Transforming the practice of medicine in Type 1 diabetes
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Transforming the practice of medicine in Type 1 diabetes TzieldTM delays the onset of First and only disease Type 1 diabetes – typically modifying therap
Slide 26: Improving access to diabetes care in Ghana
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Improving access to diabetes care in Ghana Sanofi is strengthening its commitment to improving access to prevention, treatment and care for people living
Slide 27: CHC: Sustaining robust growth
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare CHC: Sustaining robust growth Market with high growth rate Growth (MAT, in %) Positive price effect in the recent past +10.4% Pandemic-driven volume gain
Slide 28: CHC performance
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare CHC performance €1.5bn sales +11.2% Q1 2023 Digestive Wellness Allergy Q1 organic growth +12.7% €425m €276m +21.5% +17.0% 8th consecutive growth quarter
Slide 29: Enterogermina: Bellies ready!
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Enterogermina – “Bellies ready!” ®1 7 quarters of market share gain #1 Probiotic brand worldwide2 A brand linked to a purpose Engaging consumers Born in
Slide 30: Financial performance Q1 2023
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Financial performance Q1 2023
Slide 31: Double-digit EPS growth driven by sales and margin expansion
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Double-digit EPS growth driven by sales and margin expansion €m Q1 2023 Q1 2022 % Change Net Sales 10,222 9,674 +5.5% Sales growth +5.5% Other revenues 641 379 +61.7% Gross profit 7,784 7,175 +8.1% Gross
Slide 32: CHC P&L
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices CHC P&L €m Q1 2023 Q1 2022 % Change Net Sales 1,495 1,354 +11.2% Sales growth +11.2% Other revenues 15 14 +0% Gross profit 1,002 902 +12.0% Gross margin % 67.0%1 66.6%1 SG&A +8.5% R&D (53) (41) +29.3% SG&
Slide 33: Simplifying Beyfortus collaboration with AstraZeneca, agreement with Sobi
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Simplifying Beyfortus collaboration with AstraZeneca, ® simultaneously signing agreement with Sobi AstraZeneca Sobi Collaboration agreement Royalty interest agreement Sanofi acquires additional Sanofi tra
Slide 34: Outlook 2023
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Outlook 2023
Slide 35: 2023 FY business outlook
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices 2023 FY Sales P&L business • Dupixent® expected to reach €10bn • Slight improvement of gross margin due to Specialty Care outlook • Aubagio® LoE full impact growth despite Aubagio® LoE starting in Q2 • OP
Slide 36: 2023 FY guidance
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices 2023 FY guidance EPS growth Currency impact 1 Low single-digit approximately growth at CER -5.5% to -6.5% Barring unforeseen events. 1. Based on April 2023 average rates. 36 Investor Relations
Slide 37: Q&A session
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices Q&A session
Slide 38: R&D appendices
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D appendices
Slide 39: R&D Pipeline Phase III & Registration
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline Phase III & Registration Phase III Registration Name Description Indication Name Description Indication Dupixen
Slide 40: R&D Pipeline – Phase II
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline – Phase II Phase II Name Description Indication Name Description Indication Polyarticular Juvenile Idiopathic S
Slide 41: R&D Pipeline – Phase I
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline – Phase I Phase I Name Description Indication SAR441566 Oral TNF inhibitor Inflammatory indication SAR444656F,1
Slide 42: Expected major R&D milestones in 2023
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Expected major R&D milestones in 2023 H1 2023 H2 2023 COPD Positive pivotal trial readout (BOREAS) Dupixent® CIndU Efficacy
Slide 43: Expected submission timelines
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Expected submission timelines 2023 2024 2025 and beyond ®A Nexviazyme® Dupixent®A tolebrutinib Kevzara®A Dupixent Pompe Dise
Slide 44: Financial appendices
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Financial appendices
Slide 45: GenMed Q1 2023 core assets performance
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations GenMed Q1 2023 core assets performance Core asset sales (in € million) -11.9% 377 +4.4% 323 -6.5% +21.4% 289 274 261 236 243
Slide 46: Main product sales
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Main product sales Q1 2023 sales (€m) Growth Dupixent 2,316 39.7% Polio/Pertussis/Hib Vaccines 537 -11.3% Lantus 447 -32.6%
Slide 47: nirsevimab/Beyfortus initial agreement Sanofi-AstraZeneca
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations nirsevimab/Beyfortus® Initial agreement Sanofi-AstraZeneca (March 2017) Major markets (U.S., FR, DE, ES, IT, UK, JP) Rest of
Slide 48: Sanofi accounting of nirsevimab/Beyfortus: updated and new agreements
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi accounting of nirsevimab/Beyfortus® Updated and new agreements Sanofi-AstraZeneca and Sanofi-Sobi (April 2023) Update
Slide 49: Q1 sales and EPS currency impact
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Q1 sales and EPS Currency impact Company sales Business EPS €1,108m +0.31 €661m €475m +0.12 €341m +0.09 +0.07 €225m +0.04 €1
Slide 50: Net debt evolution
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Net debt evolution in 2022 € millions 6,437 -1,754 5,305 405 333 -408 292 Net Debt FCF before Proceeds Asset Restructuring O
Slide 51: 2023 currency sensitivity and Q1 2023 currency exposure
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations 2023 currency sensitivity and Q1 2023 currency exposure 2023 Business EPS currency sensitivity Currency exposure on Q1 2023
Slide 52: ESG appendices
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations ESG appendices
Slide 53: Sanofi ESG Q1 achievements
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG Q1 achievements Affordable access R&D for unmet needs Sanofi Global Health Unit Rare disease vials donation Polio
Slide 54: Sanofi ESG Q1 achievements
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG Q1 achievements Planet care In and beyond the workplace Blister-free syringe vaccines Scope 1 & 2 Diverse Senior
Slide 55: Sanofi ESG ratings
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG ratings Rating agencies 2 SCORE Climate 21.5 86/100 71/100 A Change: A B 4.3/5 3.47/5 64/100 Medium risk Water: A
Slide 56: Collaborations
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Collaborations Ref Name Developed in collaboration with… A Dupixent® Regeneron itepekimab Kevzara® B Beyfortus® AstraZeneca
Slide 57: Abbreviations
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Abbreviations Ab Antibody HCP Healthcare Professionals NKp46 Natural Killer 46-kDa protein AD Atopic Dermatitis HD High Dose
Slide 58: Strong start into 2023 R&D update Business update
Strong start into 2023 R&D update Business update Financial performance Outlook 2023 Appendices